Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study

Journal of Clinical Gastroenterology

Volumn 39, Issue 3, 2005, Pages 237-242

  Vuppalanchi, Raj ^a   Marri, Smitha ^a   Kolwankar, Dhanashri ^a   Considine, Robert V ^a   Chalasani, Naga ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Adiponectin; Insulin resistance; Nonalcoholic steatohepatitis

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR; CYTOKINE RECEPTOR; HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGE; ANTHROPOMETRY; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; MALE; NONALCOHOLIC FATTY LIVER; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPONECTIN; ADULT; FATTY LIVER; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER; MALE;

EID: 14144249423     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000152747.79773.2f     Document Type: Article

References (38)

1. McCullough AJ. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol. 2002;34:255-262.
2. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413-1419.
3. Falck-Ytter Y, Younossi ZM, Marchesini G, et al. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis. 2001;21:17-26.
4. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123:134-140.
5. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001;120:1183-1192.
6. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002;35:373-379.
7. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107:450-455.
8. Willner IR, Waters B, Patil SR, et al. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol. 2001;96:2957-2961.
9. Chalasani N, Deeg MA, Persohn S, et al. Metabolic and anthropometric evaluation of insulin resistance in nondiabetic patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003;98:1849-1855.
10. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 2004;39:188-196.
11. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology. 2003;38:1008-1017.
12. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol. 2003;38:434-440.
13. Sanyal AJ, Contos MJ, et al. A randomized controlled pilot study of pioglitazone and vitamin E versus vitamin E for nonalcoholic steatohepatitis. Hepatology. 2002;36:382A.
14. Day CP, James OF. Steatohepatitis: a tale of two 'hits?' Gastroenterology. 1998;114:842-845.
15. Younossi ZM, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology. 2002;35:746-752.
16. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37: 1202-1219.
17. Prins JB. Adipose tissue as an endocrine organ. Best Pract Res Clin Endocrinol Metab. 2002;16:639-651.
18. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol. 2003;148:293-300.
19. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003;423:762-769.
20. Xu A, Wang Y, Keshaw H, et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003;112:91-100.
21. Sanyal AJ. Insulin resistance and tissue repair: a 'fato-logical' phenomenon. Gastroenterology. 2003;125:1886-1889.
22. Bajaj M, Suraamornkul S, Piper P, et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab. 2004;89:200-206.
23. Kamada Y, Tamura S, Kiso S, et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology. 2003;125:1796-1807.
24. Hui JM, Hodge A, Farrell GC, et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology. 2004;40:46-54.
25. English PJ, Coughlin SR, Hayden K, et al. Plasma adiponectin increases postprandially in obese, but not in lean, subjects. Obes Res. 2003;11: 839-844.
26. Musso G, Gambino R, De Michieli F, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology. 2003;37:909-916.
27. Chalasani N, Gorski JC, Asghar MS, et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology. 2003;37:544-550.
28. Mather KJ, Hunt AE, Steinberg HO, et al. Repeatability characteristics of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab. 2001;86:5457-5464.
29. Congiu M, Mashford ML, Slavin JL, et al. UDP glucuronosyltransferase mRNA levels in human liver disease. Drug Metab Dispos. 2002;30: 129-134.
30. Chalasani N, Crabb DW, Cummings OW, et al. Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? Am J Gastroenterol. 2003;98:2771-2776.
31. Chalasani NDM, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in non-alcoholic steatohepatitis. Am J Gastroenterol. 2004. In press.
32. Gu HF, Abulaiti A, Ostenson CG, et al. Single nucleotide polymorphisms in the proximal promoter region of the adiponectin (APM1) gene are associated with type 2 diabetes in Swedish caucasians. Diabetes. 2004; 53(suppl 1):31-35.
33. Vasseur F, Helbecque N, Dina C, et al. Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. Hum Mol Genet. 2002;11:2607-2614.
34. Stumvoll M, Tschritter O, Fritsche A, et al. Association of the T-G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity: interaction with family history of type 2 diabetes. Diabetes. 2002;51:37-41.
35. Hara K, Boutin P, Mori Y, et al. Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes. 2002;51:536-540.
36. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab. 2002;87:2764-2769.
37. Potter JJ, Womack L, Mezey E, et al. Transdifferentiation of rat hepatic stellate cells results in leptin expression. Biochem Biophys Res Commun. 1998;244:178-182.
38. Charlton M, Sreekumar R, Rasmussen D, et al. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology. 2002;35:898-904.